Antibodies; Breakthrough infection; COVID-19; COVID-19 vaccination; Cancer patients; Correlate of protection; SARS-CoV-2; Immunoglobulin G
Abstract :
[en] The level of protection against SARS-CoV-2 breakthrough infections conferred by the presence of anti-S1 SARS-CoV-2 antibodies (IgGs) in cancer patients is still understudied. This work examines the existence of an anti-S1 immunoglobulin G (IgG) -based correlate of protection (CoP) established by prospectively collected observational data about breakthrough infections with different SARS-CoV-2 variants in a large cohort study with vaccinated cancer patients. 760 cancer patients were longitudinally followed-up, starting before first vaccination until six months after second booster. Anti-S1 SARS-CoV-2 IgGs were quantified in serum samples (N = 2958) and breakthrough infections were monitored using questionnaires, routine COVID-19 testing and medical chart review. A Generalized Estimating Equations approach was used to model the binary infection status as endpoint in relation to anti-S1 IgG titers. It is observed that higher anti-S1 IgG titers correspond to a lower probability of breakthrough infection. For the early pandemic phase, a protective anti-S1 IgG titer above 20.42 BAU/mL was observed. However, with the emergence of the Omicron variant, higher anti-S1 IgG titers are required to be protective, but no clear CoP could be identified.
Disciplines :
Immunology & infectious disease
Author, co-author :
Debie, Yana ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire ; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Garcia-Fogeda, Irene; Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Willem, Lander; Family Medicine and Population Health (FAMPOP), University of Antwerp, Doornstraat 331, 2610, Wilrijk, Belgium
Roelant, Ella; Clinical Trial Center (CTC), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium
Verbruggen, Lise; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium
Vanhoutte, Greetje; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium
Croes, Lieselot; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Vulsteke, Christof; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium ; GeIntegreerd Kankercentrum Gent (IKG), AZ Maria Middelares, Buitenring Sint-Denijs 30, 9000, Gent, Belgium
Demey, Wim; Department of Medical and Digestive Oncology, AZ Klina, Augustijnslei 100, 2930, Brasschaat, Belgium
Lybaert, Willem; Department of Medical and Digestive Oncology, VITAZ, Moerlandstraat 1, 9100, Sint-Niklaas, Belgium
Hanssens, Marianne; Kankercentrum Medische Oncologie, AZ Groeninge, President Kennedylaan 4, 8500, Kortrijk, Belgium
Van Ongeval, Johan; Department of Gastroenterology and Digestive Oncology, AZ Sint-Lucas Gent, Groenebriel 1, 9000, Gent, Belgium
De Becker, Ann; Department of Hematology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium
Jansens, Hilde; Department of Laboratory Medicine, Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium
Goossens, Maria E; SD Infectious Diseases in Humans, Platform Interventional Studies, Sciensano, Rue Juliette Wytsmanstraat 14, 1050, Brussels, Belgium
Janssens, Annelies; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Prenen, Hans; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Anguille, Sébastien; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Division of Hematology, Antwerp University Hospital (UZA), Drie Eikenstraat 655, 2650, Edegem, Belgium
Peeters, Marc; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
van Dam, Peter A; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium
Hens, Niel; Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium ; Data Science Institute, Interuniversity Institute of Biostatistics and Statistical Bioinformatics, UHasselt, Martelarenlaan 42, 3500, Hasselt, Belgium
Abrams, Steven; Family Medicine and Population Health (FAMPOP), University of Antwerp, Doornstraat 331, 2610, Wilrijk, Belgium ; Data Science Institute, Interuniversity Institute of Biostatistics and Statistical Bioinformatics, UHasselt, Martelarenlaan 42, 3500, Hasselt, Belgium
Vandamme, Timon; Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium. Timon.vandamme@uza.be ; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610, Wilrijk, Belgium. Timon.vandamme@uza.be
Kom op tegen Kanker FWO - Fonds Wetenschappelijk Onderzoek Vlaanderen
Funding text :
We are grateful to the BelCoVac consortium for data sharing and scientific contribution to the project. We kindly thank the B-VOICE, Tri-VOICE plus and REAL-V participants for study participation, the staff members of the Biobank Antwerp and all recruiting physicians. We are thankful to Siddharth Chhajlani, Sven De Keersmaecker, Silke Raats, Isolde Van der Massen, Lisa Verheggen and Sanne Wouters for logistic support and coordination. We wish to acknowledge Kim Claes for the prompt and efficient set-up of the online questionnaires. In addition, we thank the B-VOICE, Tri-VOICE plus and REAL-V study teams from all recruiting centers for patient inclusion and sample collection and the clinical biology study team for performing serological analysis. This work was supported by the Belgian Government through Sciensano (Grant Nos. COVID-19_SC004, COVID-19_SC059, COVID-19_SC061) and Kom op tegen Kanker (KOTK_UZA/2020/12604/1). T. Vandamme is holder of Senior Clinical Investigator Grant 1803723 N of the Research Foundation - Flanders (Belgium) (FWO).We are grateful to the BelCoVac consortium for data sharing and scientific contribution to the project. We kindly thank the B-VOICE, Tri-VOICE plus and REAL-V participants for study participation, the staff members of the Biobank Antwerp and all recruiting physicians. We are thankful to Siddharth Chhajlani, Sven De Keersmaecker, Silke Raats, Isolde Van der Massen, Lisa Verheggen and Sanne Wouters for logistic support and coordination. We wish to acknowledge Kim Claes for the prompt and efficient set-up of the online questionnaires. In addition, we thank the B-VOICE, Tri-VOICE plus and REAL-V study teams from all recruiting centers for patient inclusion and sample collection and the clinical biology study team for performing serological analysis. This work was supported by the Belgian Government through Sciensano (Grant Nos. COVID-19_SC004, COVID-19_SC059, COVID-19_SC061) and Kom op tegen Kanker (KOTK_UZA/2020/12604/1). T. Vandamme is holder of Senior Clinical Investigator Grant 1803723\u00A0N of the Research Foundation - Flanders (Belgium) (FWO).
R.B. Martines et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, united States Emerg. Infect. Dis. 26 2005 2015 1:CAS:528:DC%2BB3cXitlyltrjO 10.3201/eid2609.202095 32437316 7454055 1465.35237
A.G. Harrison T. Lin P. Wang Mechanisms of SARS-CoV-2 transmission and pathogenesis Trends Immunol. 41 1100 1115 1:CAS:528:DC%2BB3cXitFWisLvN 10.1016/j.it.2020.10.004 33132005 7556779 1471.91488
C. Chakraborty A.R. Sharma G. Sharma M. Bhattacharya S.S. Lee SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options Eur. Rev. Med. Pharmacol. Sci. 24 4016 4026 1:STN:280:DC%2BB38zptFCmtg%3D%3D 10.26355/eurrev_202004_20871 32329877 1538.11134
A.L. Schmidt et al. COVID-19 vaccination and breakthrough infections in patients with cancer Ann. Oncol. 33 340 346 1:CAS:528:DC%2BB38XhtVamtbjL 10.1016/j.annonc.2021.12.006 34958894 1235.74047
S. Galmiche et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review Clin. Microbiol. Infect. 28 163 177 1:CAS:528:DC%2BB38Xit1elur0%3D 10.1016/j.cmi.2021.09.036 35020589 0951.03055
R.H. Patel R. Vanaparthy J.N. Greene COVID-19 in immunocompromised Cancer patients: A case series and review of the literature Cancer Control 28 10732748211044361 10.1177/10732748211044361 34579537 8482717
P. van Dam et al. Immunoglobin g/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests Eur. J. Cancer 148 328 339 1:CAS:528:DC%2BB3MXnsVGht74%3D 10.1016/j.ejca.2021.02.024 33773276 7914028
A. Fendler et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety Nat. Rev. Clin. Oncol. 19 385 401 1:CAS:528:DC%2BB38Xnt1Oqs70%3D 10.1038/s41571-022-00610-8 35277694 8916486 0651.46051
O.J. Watson et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study Lancet Infect. Dis. 22 1293 1302 1:CAS:528:DC%2BB38Xhs1CkurvO 10.1016/s1473-3099(22)00320-6 35753318 9225255 0983.65019
E. Amanatidou et al. Breakthrough infections after COVID-19 vaccination: insights, perspectives and challenges Metabolism Open. 14 100180 1:CAS:528:DC%2BB38XnslSitb8%3D 10.1016/j.metop.2022.100180 35313532 8928742 1121.74318
T. Brosh-Nissimov et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel Clin. Microbiol. Infect. 27 1652 1657 1:CAS:528:DC%2BB3MXhs1ClsLvF 10.1016/j.cmi.2021.06.036 34245907 8261136 07480104
M. Peeters et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment ESMO Open. 6 100274 1:STN:280:DC%2BB2cnltFSqtg%3D%3D 10.1016/j.esmoop.2021.100274 34597941 8423808
I.Y. Gong et al. Association of COVID-19 vaccination with breakthrough infections and complications in patients with Cancer JAMA Oncol. 9 386 394 10.1001/jamaoncol.2022.6815 36580318 1213.82062
L.Y.W. Lee et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study Lancet Oncol. 23 748 757 1:CAS:528:DC%2BB38XhsVWgtLfP 10.1016/s1470-2045(22)00202-9 35617989 9126559 1490.90135
L.B. Shrestha C. Foster W. Rawlinson N. Tedla R.A. Bull Evolution of the SARS-CoV-2 Omicron variants BA.1 to BA.5: implications for immune escape and transmission Rev. Med. Virol. 32 e2381 1:CAS:528:DC%2BB38XitVWksr%2FO 10.1002/rmv.2381 35856385 9349777
B.J. Willett et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway Nat. Microbiol. 7 1161 1179 1:CAS:528:DC%2BB38XhslGgtL7I 10.1038/s41564-022-01143-7 35798890 9352574 1515.46013
T. Braeye et al. Vaccine effectiveness against transmission of alpha, delta and Omicron SARS-COV-2-infection, Belgian contact tracing, 2021–2022 Vaccine 41 3292 3300 1:CAS:528:DC%2BB3sXotFCktLk%3D 10.1016/j.vaccine.2023.03.069 37085456 10073587 1530.20124
O.M. Espíndola et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or coronavac and heterologous boosting Sci. Rep. 13 7437 2023NatSR.13.7437E 1:CAS:528:DC%2BB3sXpvFSjsbc%3D 10.1038/s41598-023-34035-9 37156846 10165291 1518.93014
S.Y. Ren W.B. Wang R.D. Gao A.M. Zhou Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance World J. Clin. Cases 10 1 11 10.12998/wjcc.v10.i1.1 35071500 8727245
Y. Araf et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines J. Med. Virol. 10.1002/jmv.27588 35815524 9015557 1508.92317
A. Lasagna et al. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study ESMO Open. 7 100458 1:STN:280:DC%2BB2MvnvFSrtQ%3D%3D 10.1016/j.esmoop.2022.100458 35427842 8913298 1391.37021
D.S. Khoury et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Nat. Med. 27 1205 1211 1:CAS:528:DC%2BB3MXhtFSktLrP 10.1038/s41591-021-01377-8 34002089 1523.35097
S.A. Plotkin P.B. Gilbert Nomenclature for immune correlates of protection after vaccination Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. 54 1615 1617 10.1093/cid/cis238 1309.94084
F. Krammer A correlate of protection for SARS-CoV-2 vaccines is urgently needed Nat. Med. 27 1147 1148 1:CAS:528:DC%2BB3MXhsFSktL3K 10.1038/s41591-021-01432-4 34239135 0988.20023
Debie, Y., Vandamme, T., Goossens, M. E., van Dam, P. A. & Peeters, M. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in Cancer patients. Eur. J. Cancer https://doi.org/10.1016/j.ejca.2021.12.025
Y. Debie et al. Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following Double-Dose vaccination with BNT162b2 versus ChAdOx1 in patients with Cancer Clin. cancer Research: Official J. Am. Association Cancer Res. 29 635 646 1:CAS:528:DC%2BB3sXlt1Kmtb4%3D 10.1158/1078-0432.Ccr-22-2185
Y. Debie P.A. van Dam M.E. Goossens M. Peeters T. Vandamme Boosting capacity of a fourth dose BNT162b2 in cancer patients Eur. J. Cancer 179 121 123 1:CAS:528:DC%2BB38XjtFWgsb%2FL 10.1016/j.ejca.2022.11.016 36521333
M. Cuykx et al. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays Diagn. Microbiol. Infect. Dis. 101 115486 1:CAS:528:DC%2BB3MXhs1OhsbvP 10.1016/j.diagmicrobio.2021.115486 34332306 8272050 1523.60060
C. Irsara et al. Clinical validation of the Siemens quantitative SARS-CoV-2 Spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers Clin. Chem. Lab. Med. 59 1453 1462 1:CAS:528:DC%2BB3MXhsFSitLbF 10.1515/cclm-2021-0214 33837679 1475.35227
Sciensano The COVID-19 Test Results data collection, (2022). https://docs.healthdata.be/documentation/covid-19-test-results/covid-19-test-results-data-collection
RCoreTeam. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing (2023). https://www.R-project.org/
WHO. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know (2022). https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know
WHO. The Moderna COVID-19 (mRNA-1273) vaccine: What you need to know (2022). https://www.who.int/news-room/feature-stories/detail/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know
A. Fendler et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study Nat. cancer 2 1321 1337 1:CAS:528:DC%2BB3MXislKjs7zF 10.1038/s43018-021-00274-w 35121900 7612125 1284.47049
Y. Chong et al. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents Influenza Other Respir Viruses 16 1066 1071 1:CAS:528:DC%2BB38XitF2kurzN 10.1111/irv.13030 35962568 9530588 1209.62034
N.E. Aikawa et al. Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine Rheumatol. (Oxford England) 10.1093/rheumatology/keac301 1074.31003
J. Barrière et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: should humoral responses be monitored? A position Article Eur. J. Cancer 162 182 193 1:CAS:528:DC%2BB38Xnt1SgtA%3D%3D 10.1016/j.ejca.2021.12.011 35016032 1398.68005
R. Grewal et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the Omicron variant among long term care residents in Ontario, Canada: test negative design study BMJ (Clinical Res. ed.) 378 e071502 10.1136/bmj-2022-071502 1522.83252
A. Massarweh et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for Cancer JAMA Oncol. 7 1133 1140 10.1001/jamaoncol.2021.2155 34047765
N. Kamar et al. Three doses of an mRNA Covid-19 vaccine in Solid-Organ transplant recipients N Engl. J. Med. 385 661 662 10.1056/NEJMc2108861 34161700 1033.34015
N. Eliakim-Raz et al. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged ≥ 60 years JAMA 10.1001/jama.2021.19885 34739043 8652594
I. Cohen S. Campisi-Pfinto O. Rozenberg R. Colodner G. Bar-Sela The humoral response of patients with Cancer to breakthrough COVID-19 infection or the fourth BNT162b2 vaccine dose Oncologist 28 e225 e227 10.1093/oncolo/oyad003 36856804 10078898
A.S. Lauring et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from Omicron, delta, and alpha SARS-CoV-2 variants in the united States: prospective observational study BMJ (Clinical Res. ed.) 376 e069761 10.1136/bmj-2021-069761
J.L. Piñana et al. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients Blood Cancer J. 13 8 10.1038/s41408-022-00778-3 36599843 9812742 1504.92139
R. Wijaya et al. Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing Lancet 402 99 102 10.1016/s0140-6736(23)01180-7 37393922 1462.76129
L. Seekircher et al. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial Lancet Microbe 4 e612 e621 1:CAS:528:DC%2BB2cXkslOhs7c%3D 10.1016/s2666-5247(23)00107-6 37354911 07858736
S. Feng et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Nat. Med. 27 2032 2040 1:CAS:528:DC%2BB3MXitFCit7%2FL 10.1038/s41591-021-01540-1 34588689 8604724 1482.60110
K.A. Earle et al. Evidence for antibody as a protective correlate for COVID-19 vaccines Vaccine 39 4423 4428 1:CAS:528:DC%2BB3MXhsV2ltrrK 10.1016/j.vaccine.2021.05.063 34210573 8142841 1401.93083
M.H. Kim et al. Antibody level predicts the clinical course of breakthrough infection of COVID-19 caused by Delta and Omicron variants: A prospective Cross-Sectional study Open. Forum Infect. Dis. 9 ofac262 1:CAS:528:DC%2BB38XhvVGqs7fO 10.1093/ofid/ofac262 35855960 9129209
W.Y. Chi et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection J. Biomed. Sci. 29 82 10.1186/s12929-022-00853-8 36243868 9569411 0814.15022
M. Bergwerk et al. Covid-19 breakthrough infections in vaccinated health care workers N Engl. J. Med. 385 1474 1484 1:CAS:528:DC%2BB3MXit1Crt7jN 10.1056/NEJMoa2109072 34320281 1521.62551
D. Goldblatt et al. Towards a population-based threshold of protection for COVID-19 vaccines Vaccine 40 306 315 1:CAS:528:DC%2BB38XntFyhtw%3D%3D 10.1016/j.vaccine.2021.12.006 34933765 07823894
G. Zhou et al. The dynamics of B-cell reconstitution post allogeneic hematopoietic stem cell transplantation: A real-world study J. Intern. Med. 295 634 650 1:CAS:528:DC%2BB2cXlvVWmsb0%3D 10.1111/joim.13776 38439117 1343.90063
M.R. van den Brink E. Velardi M.A. Perales Immune reconstitution following stem cell transplantation Hematol. Am. Soc. Hematol. Educ. Program. 2015 215 219 10.1182/asheducation-2015.1.215
A. Sharma S. Jasrotia A. Kumar Effects of chemotherapy on the immune system: implications for Cancer treatment and patient outcomes Naunyn Schmiedebergs Arch. Pharmacol. 397 2551 2566 1:CAS:528:DC%2BB3sXit1KgtLrO 10.1007/s00210-023-02781-2 37906273 0979.93129
L. Zitvogel L. Apetoh F. Ghiringhelli G. Kroemer Immunological aspects of cancer chemotherapy Nat. Rev. Immunol. 8 59 73 1:CAS:528:DC%2BD2sXhsVKrsLnP 10.1038/nri2216 18097448
D. Goldblatt G. Alter S. Crotty S.A. Plotkin Correlates of protection against SARS-CoV-2 infection and COVID-19 disease Immunol. Rev. 310 6 26 1:CAS:528:DC%2BB38XhsVGnsrbM 10.1111/imr.13091 35661178
Y. Liu H. Arase Neutralizing and enhancing antibodies against SARS-CoV-2 Inflamm. Regen 42 58 1:CAS:528:DC%2BB38XjtVOjt7jJ 10.1186/s41232-022-00233-7 36471381 9720987 1505.92053
K. McMahan et al. Correlates of protection against SARS-CoV-2 in rhesus macaques Nature 590 630 634 2021Natur.590.630M 1:CAS:528:DC%2BB3MXht1Onu7c%3D 10.1038/s41586-020-03041-6 33276369 1524.68284
E.R. DeLong D.M. DeLong D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 837 845 1:STN:280:DyaL1M%2Fns12ksQ%3D%3D 10.2307/2531595 3203132 0715.62207
